Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca’s Crestor Label Revised With Stronger Rhabdomyolysis Warnings

This article was originally published in The Pink Sheet Daily

Executive Summary

Labeling now emphasizes increased risk of rhabdomyolysis, especially at 40 mg dose, but FDA reaffirms that muscle toxicity is seen across the statin class and is not unique to rosuvastatin. Labeling also recommends caution in dosing in patients of Asian descent due to increased elevation in rosuvastatin exposure.

You may also be interested in...



Canada Updates Statin Labeling On Muscle Toxicity, Adds Predisposing Factors

Health Canada universalizes statin safety labeling; warning adds list of predisposing factors for rhabdomyolysis and myopathy. Lists are similar to U.S. labeling, but not identical.

Canada Updates Statin Labeling On Muscle Toxicity, Adds Predisposing Factors

Health Canada universalizes statin safety labeling; warning adds list of predisposing factors for rhabdomyolysis and myopathy. Lists are similar to U.S. labeling, but not identical.

Zocor Labeling Adds Two Drug Interactions To Myopathy/Rhabdo Warning

Telithromycin and danazol should be avoided with use of simvastatin due to increased risk of myopathy/rhabdomyolysis, revised labeling states. Danazol interaction increases with higher doses of Zocor.

Related Content

Topics

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel